Abstract 487P
Background
The United States Preventive Services Task Force (USPSTF) recommends low dose CT screening for lung cancer in individuals (1) 50-80 years old, (2) currently smoking or had quit for less than 15 years and (3) had at least a 20 pack-year smoking history. It is unclear if these guidelines will be applicable to our mixed Asian population. Our aim is to evaluate the performance of the USPSTF lung cancer screening criteria in our population of lung cancer patients.
Methods
We retrospectively reviewed the records of all asymptomatic patients who underwent resection of primary lung cancer in our institution between 2019 and 2021. Data collected included demographics, smoking status, histology and the final staging.
Results
We reviewed 259 consecutive cases of resectable primary lung cancer patients between 2019 and 2021. 145 patients were males (56.0%) and 114 patients were females (44.0%). There were 123 (47.5%) active or former smokers and 136 (52.5%) non-smokers. 83 patients (32.0%) met the USPSTF screening criteria and 176 patients (68.0%) did not. Lowering the age criteria to 45 years old increased the pickup rate to 34.4%. Male patients were more likely to meet the criteria (OR 2.27, 95% CI 1.87-2.76, p < 0.001) than female patients. The pickup rate increased significantly to 40.5% when patients who had stopped smoking for more than 15 years were included (p < 0.001) and 44.4% (p < 0.001) when patients who smoked less than 20 pack years were included. Screening by age criteria alone resulted in a pickup rate of 93.8% (males 94.5%, females 93.0%). Within this age range, the pickup rate in females was 84.2% in non-smokers and 8.8% in active or former smokers whilst the pickup rate in male was 22.1% in non-smokers and 72.4% in active or former smokers.
Conclusions
Our study showed the performance of the USPSTF criteria when applied to a mixed Asian population. It is concerning that more than two-thirds of patients will miss the opportunity for early curative resection if the guidelines were followed. A significant proportion of our patients were non-smokers, especially in the female population. A lung screening programme will need to be refined from existing guidelines to fit our local mixed Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract